Fierce Pharma

JULY 11, 2024

Even as pharma companies have yet to feel the full effects of the Inflation Reduction Act, Senate lawmakers have turned their attention to another facet of drug pricing with a bill meant to cr | The bill looks to limit the number of patents that companies can assert in litigation on individual products. It's intended to crack down on "patent thickets," which can delay and thwart generic competition.

Pharma 309

Pharma Competition 309

Clarivate

JULY 11, 2024

“AI Everywhere All at Once.” This year’s theme from Outsell, Inc. perfectly captures the expansion of artificial intelligence across all facets of our lives. In academia, this rapid advancement raises more questions than answers. How do we ensure ethical AI use? How can we advance research and drive research integrity? How do we use AI to advance student learning skills?

Ethics 122

Ethics Education Marketing Government 122

Fierce Pharma

JULY 11, 2024

Following this month's FDA approval of Eli Lilly’s amyloid-busting antibody Kisunla (donanemab), the Alzheimer’s disease market is set to grow in earnest—and Lilly is already eyeing a spot at the t | On top of Eisai and Biogen's Leqembi, Kisunla’s approval likely marks the “end of the beginning in treating this disease,” Andrew Lechleiter, VP of U.S.

Marketing 286

Marketing FDA 286

pharmaphorum

JULY 11, 2024

The US Senate has come together to pass a bill that aims to prevent pharma companies from filing multiple patents around biologic drugs as a way to delay biosimilar competitors.Lawmakers unanimously passed the Affordable Prescriptions for Patients Act of 2023 (S-150), which is part of a lengthening list of measures being taken by Congress to curb the prices of medicines in the US.

Prescription 115

Prescription Medicine Pharma Patients 115

Advertisement

Fierce Pharma

JULY 11, 2024

Freshly equipped with two approved meds from Acorda Therapeutics, Frankfurt, Germany’s Merz Therapeutics is kicking its specialty neurology ambitions into high gear. | Equipped with two approved meds from Acorda Therapeutics, Germany’s Merz Therapeutics is kicking its specialty neurology ambitions into high gear.

226

226

MedCity News

JULY 11, 2024

By understanding that AUD is a diagnosable and treatable medical condition with individualized impact, we can tailor treatments to meet patients’ specific needs. Effective treatment for AUD is multifaceted, involving medical, psychological, and social support. The post Closing the Gap in Medications for the Treatment of Alcohol Use Disorder (AUD) appeared first on MedCity News.

Medical 114

Medical Patients FDA Biopharma 114

MedCity News

JULY 11, 2024

Amedisys and UnitedHealth Group plan to divest care centers to an affiliate of VitalCaring Group. Several experts said this will likely clear the way for the companies’ merger. The post Will A Divestiture Save the UnitedHealth Group-Amedisys Deal? appeared first on MedCity News.

114

114

Fierce Pharma

JULY 11, 2024

AbbVie is asking the U.S. | AbbVie is asking the U.S. Supreme Court to overrule a lower court's ruling that the company must turn over records of communications with its lawyers regarding a patent lawsuit it filed against a generic drug maker more than a decade ago.

206

206

European Pharmaceutical Review

JULY 11, 2024

Dr Roopal Thakkar has been appointed as Executive Vice President, Research & Development and Chief Scientific Officer of AbbVie. He is the company ’s current Senior Vice President, Chief Medical Officer, Global Therapeutics. “As AbbVie’s Chief Scientific Officer, Dr Thakkar will continue to build momentum across discovery and all stages of development to fully realise the potential of our diverse pipeline.

Medicine 105

Medicine Medical Leads Training 105

Fierce Pharma

JULY 11, 2024

The dog days of summer might be in full swing, but for flu vaccine makers, its a busy time prepping for this fall's influenza season. | The companies started distributing shipments of their respective vaccine options ahead of the fall flu season as the CDC recommends vaccination before the virus spreads.

Distribution 201

Distribution 201

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Safety

pharmaphorum

JULY 11, 2024

The FTC is said to be gearing up to file lawsuits against the top three pharmacy benefit managers in the wake of its damning report on the sector.

Management 108

Management 108

Fierce Pharma

JULY 11, 2024

After a rocky road to approval and two amendments to the original pact, Akebia Therapeutics and CSL Vifor have terminated their collaboration around the oral chronic kidney disease (CKD) anemia dru | As it ends a licensing agreement with CSL Vifor, Akebia has priced its chronic kidney disease anemia drug Vafseo by incorporating an uncertain future label expansion that it plans to discuss with the FDA later this year.

FDA 200

FDA 200

pharmaphorum

JULY 11, 2024

Tune in to Caroline Redecker and Jason Casarella as they discuss clinical trial trends and the rise of site networks in this insightful podcast episode brought to you by Advanced Clinical.

Networking 92

Networking 92

Fierce Pharma

JULY 11, 2024

In this episode of "The Top Line", sponsored by the Parenteral Drug Association (PDA), we do a deep dive into the highly anticipated PDA/FDA Joint Regulatory Conference, set to take place from Sept | We sat down with industry expert Janeen Skutnik-Wilkinson, the PDA/FDA Joint Regulatory Conference 2024 Co-Chair to give us an exclusive behind-the-scenes look at this must-attend CGMP event, set to take place from September 9-11 in Washington D.C.

FDA 130

FDA 130

Advertisement

Distribution

MedCity News

JULY 11, 2024

Ipsen has acquired global rights to a Foreseen Biotechnology antibody drug conjugate developed for an undisclosed cancer target. This is Ipsen’s second ADC deal in three months, following its acquisition of rights to a ROR1-targeting ADC from Sutro Biophrama. The post Ipsen Turns to China-Based Biotech to Get Another ADC Cancer Drug appeared first on MedCity News.

Biopharma 90

Biopharma Pharma 90

pharmaphorum

JULY 11, 2024

FDA rejects Novo Nordisk’s once-weekly basal insulin for people with diabetes, which would reduce the number of injections needed

FDA 101

FDA 101

MedCity News

JULY 11, 2024

Solving three major challenges in the development of new oncology drugs The post The Opportunity for Digital Innovation in Oncology Drug Development appeared first on MedCity News.

FDA 73

FDA Patients Pharma 73

PharmaTimes

JULY 11, 2024

Macmillan Cancer Support estimates that cancer affects over three million people in the UK

Government 104

Government 104

Advertisement

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

Safety

pharmaphorum

JULY 11, 2024

Ipsen places another bet on an antibody-drug conjugate for cancer, pledging up to $1bn for a preclinical candidate from Foreseen Bio

84

84

MedCity News

JULY 11, 2024

The number of hospital M&A deals may have fallen from Q1 to Q2 of this year, but that doesn’t mean that the hospital M&A space is lacking vitality, according to a new Kaufman Hall report. Rather, it means that the hospital M&A is shifting its emphasis from scale to strategy. The post Hospital M&A Activity Remained Strong In Q2, Kaufman Hall Says appeared first on MedCity News.

65

65

pharmaphorum

JULY 11, 2024

Change of R&D chiefs at AbbVie, as Thomas Hudson steps down as CSO and is replaced by Roopal Thakkar.

89

89

PharmaTimes

JULY 11, 2024

The ESRC EquaDem Network Plus aims to improve disparities in diagnosis and care

Networking 89

Networking 89

Advertisement

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

Distribution

Pharmaceutical Commerce

JULY 11, 2024

The latest news for pharma industry insiders.

Pharma 105

Pharma 105

Scott’s Directories

JULY 11, 2024

In Manitoba, the healthcare sector thrives, offering vast market opportunities. For businesses targeting this industry, access to a comprehensive physician directory in Manitoba is invaluable. Whether you’re a pharmaceutical company, a medical equipment supplier, or a healthcare recruiter, having a detailed Manitoba medical directory can significantly enhance your outreach efforts.

Doctors 52

Doctors Marketing Physicians Medical 52

Clarify Health

JULY 11, 2024

As health plans seek innovative strategies to enhance their service offerings and improve financial performance, the integration of telemedicine into their networks emerges as a pivotal solution. By leveraging data analytics to optimize and expand telemedicine capabilities, payers can effectively address the critical challenge of extending quality healthcare to underserved areas while managing costs.

Networking 52

Networking Healthcare Healthcare Patients 52

Contrarian Sales Techniques

JULY 11, 2024

Meet Wei Wei isn't your typical high-flying pharma rep. Forget fancy suits and briefcases overflowing with brochures for the latest wonder drug. This 50-year-old rolls up his sleeves and hits the dusty roads in his trusty Perodua Alza, a familiar sight in the rural areas he frequents. The truth is, Wei used to be that kind of rep. All charm and spiel, pushing expensive branded meds on busy doctors.

Doctors 52

Doctors Medical Sales Pharma reps 52

Advertisement

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

Leads

Pharmaceutical Commerce

JULY 11, 2024

In an interview with Pharma Commerce editor Nicholas Saraceno, Peter Ax, UpScriptHealth’s founder and CEO, discusses how patients are affected by these supply chain bottlenecks, along with ways to mitigate these complications.

Patients 52

Patients Pharma 52

PharmExec

JULY 11, 2024

According to the Complete Response Letter, the FDA has requested additional information on the manufacturing process and the type 1 diabetes indication for insulin icodec before completing its review.

FDA 52

FDA Manufacturing 52

Pharmacy Times

JULY 11, 2024

In a follow-up to the interim FTC report documenting the business practices of PBMs and the power they hold in the pharmaceutical industry, the Commission now seeks to sue the 3 largest PBMs in the country for driving up the price of insulin and other essential drugs.

Management 64

Management Pharmaceutical 64

PharmExec

JULY 11, 2024

Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.

FDA 52

FDA Medical Marketing 52

Advertisement

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.

Specialization